JP2007506803A5 - - Google Patents

Info

Publication number

JP2007506803A5

JP2007506803A5 JP2006533446A JP2006533446A JP2007506803A5 JP 2007506803 A5 JP2007506803 A5 JP 2007506803A5 JP 2006533446 A JP2006533446 A JP 2006533446A JP 2006533446 A JP2006533446 A JP 2006533446A JP 2007506803 A5 JP2007506803 A5 JP 2007506803A5

Authority

JP

Japan

Prior art keywords

aliphatic

aryl

heteroaryl

heterocyclyl

cycloaliphatic

Prior art date

2004-05-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims description 132
• 238000000034 method Methods 0.000 claims description 112
• -1 1,2-methylenedioxy Chemical group 0.000 claims description 92
• 239000000203 mixture Substances 0.000 claims description 58
• 229910052757 nitrogen Inorganic materials 0.000 claims description 58
• 125000001424 substituent group Chemical group 0.000 claims description 56
• 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 50
• 108010076667 Caspases Proteins 0.000 claims description 36
• 102000011727 Caspases Human genes 0.000 claims description 35
• 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 34
• 229910052760 oxygen Inorganic materials 0.000 claims description 33
• 210000004027 cell Anatomy 0.000 claims description 32
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
• 125000004429 atom Chemical group 0.000 claims description 30
• 230000006907 apoptotic process Effects 0.000 claims description 29
• 125000003118 aryl group Chemical group 0.000 claims description 28
• 201000010099 disease Diseases 0.000 claims description 28
• 229910052739 hydrogen Inorganic materials 0.000 claims description 27
• 239000001257 hydrogen Substances 0.000 claims description 27
• 125000001072 heteroaryl group Chemical group 0.000 claims description 26
• 125000001931 aliphatic group Chemical group 0.000 claims description 25
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
• 239000002904 solvent Substances 0.000 claims description 23
• 125000005842 heteroatom Chemical group 0.000 claims description 21
• 229910052736 halogen Inorganic materials 0.000 claims description 19
• 239000008194 pharmaceutical composition Substances 0.000 claims description 18
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 16
• 125000006574 non-aromatic ring group Chemical group 0.000 claims description 16
• 125000000464 thioxo group Chemical group S=* 0.000 claims description 16
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
• 125000000623 heterocyclic group Chemical group 0.000 claims description 14
• 229910052717 sulfur Inorganic materials 0.000 claims description 14
• 150000002367 halogens Chemical class 0.000 claims description 13
• 230000001404 mediated effect Effects 0.000 claims description 10
• 208000011580 syndromic disease Diseases 0.000 claims description 10
• 125000001475 halogen functional group Chemical group 0.000 claims description 7
• 210000000056 organ Anatomy 0.000 claims description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
• 230000008878 coupling Effects 0.000 claims description 6
• 238000010168 coupling process Methods 0.000 claims description 6
• 238000005859 coupling reaction Methods 0.000 claims description 6
• 208000015181 infectious disease Diseases 0.000 claims description 6
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
• 208000020084 Bone disease Diseases 0.000 claims description 5
• 208000034578 Multiple myelomas Diseases 0.000 claims description 5
• 230000001154 acute effect Effects 0.000 claims description 5
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
• 230000001684 chronic effect Effects 0.000 claims description 5
• 210000004351 coronary vessel Anatomy 0.000 claims description 5
• 125000004122 cyclic group Chemical group 0.000 claims description 5
• 239000003814 drug Substances 0.000 claims description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• 238000011282 treatment Methods 0.000 claims description 5
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
• 208000002193 Pain Diseases 0.000 claims description 4
• 208000006011 Stroke Diseases 0.000 claims description 4
• 230000030833 cell death Effects 0.000 claims description 4
• 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims description 4
• 238000010511 deprotection reaction Methods 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 208000024908 graft versus host disease Diseases 0.000 claims description 4
• 208000019622 heart disease Diseases 0.000 claims description 4
• 208000027866 inflammatory disease Diseases 0.000 claims description 4
• 230000001590 oxidative effect Effects 0.000 claims description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 4
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
• 208000023275 Autoimmune disease Diseases 0.000 claims description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
• 208000023328 Basedow disease Diseases 0.000 claims description 3
• 201000006474 Brain Ischemia Diseases 0.000 claims description 3
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
• 206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
• 208000011231 Crohn disease Diseases 0.000 claims description 3
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
• 208000015023 Graves' disease Diseases 0.000 claims description 3
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
• 206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
• 108010074328 Interferon-gamma Proteins 0.000 claims description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
• 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
• 208000028389 Nerve injury Diseases 0.000 claims description 3
• 208000001132 Osteoporosis Diseases 0.000 claims description 3
• 206010033645 Pancreatitis Diseases 0.000 claims description 3
• 201000004681 Psoriasis Diseases 0.000 claims description 3
• 206010039710 Scleroderma Diseases 0.000 claims description 3
• 206010040047 Sepsis Diseases 0.000 claims description 3
• 206010043781 Thyroiditis chronic Diseases 0.000 claims description 3
• 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
• 208000006673 asthma Diseases 0.000 claims description 3
• 201000005000 autoimmune gastritis Diseases 0.000 claims description 3
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
• 230000001580 bacterial effect Effects 0.000 claims description 3
• 206010008118 cerebral infarction Diseases 0.000 claims description 3
• 208000001848 dysentery Diseases 0.000 claims description 3
• 150000002431 hydrogen Chemical class 0.000 claims description 3
• 230000002458 infectious effect Effects 0.000 claims description 3
• 230000002757 inflammatory effect Effects 0.000 claims description 3
• 208000021039 metastatic melanoma Diseases 0.000 claims description 3
• 206010028417 myasthenia gravis Diseases 0.000 claims description 3
• 208000010125 myocardial infarction Diseases 0.000 claims description 3
• 208000031225 myocardial ischemia Diseases 0.000 claims description 3
• 230000008764 nerve damage Effects 0.000 claims description 3
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
• 230000000926 neurological effect Effects 0.000 claims description 3
• 201000008482 osteoarthritis Diseases 0.000 claims description 3
• 125000004043 oxo group Chemical group O=* 0.000 claims description 3
• 230000035939 shock Effects 0.000 claims description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
• 206010043554 thrombocytopenia Diseases 0.000 claims description 3
• 230000009529 traumatic brain injury Effects 0.000 claims description 3
• 239000003981 vehicle Substances 0.000 claims description 3
• 208000034950 Acinetobacter Infections Diseases 0.000 claims description 2
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
• 201000004384 Alopecia Diseases 0.000 claims description 2
• 208000024827 Alzheimer disease Diseases 0.000 claims description 2
• 201000001320 Atherosclerosis Diseases 0.000 claims description 2
• 208000027496 Behcet disease Diseases 0.000 claims description 2
• 208000009137 Behcet syndrome Diseases 0.000 claims description 2
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
• 208000000094 Chronic Pain Diseases 0.000 claims description 2
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
• 208000035473 Communicable disease Diseases 0.000 claims description 2
• 208000001490 Dengue Diseases 0.000 claims description 2
• 206010012310 Dengue fever Diseases 0.000 claims description 2
• 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
• 208000000059 Dyspnea Diseases 0.000 claims description 2
• 206010013975 Dyspnoeas Diseases 0.000 claims description 2
• 206010014561 Emphysema Diseases 0.000 claims description 2
• 206010014596 Encephalitis Japanese B Diseases 0.000 claims description 2
• 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 2
• 208000035690 Familial cold urticaria Diseases 0.000 claims description 2
• 201000005569 Gout Diseases 0.000 claims description 2
• 208000031886 HIV Infections Diseases 0.000 claims description 2
• 208000037357 HIV infectious disease Diseases 0.000 claims description 2
• 206010019280 Heart failures Diseases 0.000 claims description 2
• 241000590002 Helicobacter pylori Species 0.000 claims description 2
• 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 2
• 208000005176 Hepatitis C Diseases 0.000 claims description 2
• 206010019773 Hepatitis G Diseases 0.000 claims description 2
• 208000032672 Histiocytosis haematophagic Diseases 0.000 claims description 2
• 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims description 2
• 208000023105 Huntington disease Diseases 0.000 claims description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
• 102000000589 Interleukin-1 Human genes 0.000 claims description 2
• 108010002352 Interleukin-1 Proteins 0.000 claims description 2
• 102100039898 Interleukin-18 Human genes 0.000 claims description 2
• 201000005807 Japanese encephalitis Diseases 0.000 claims description 2
• 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
• 208000027747 Kennedy disease Diseases 0.000 claims description 2
• 208000004987 Macrophage activation syndrome Diseases 0.000 claims description 2
• 201000009906 Meningitis Diseases 0.000 claims description 2
• 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
• 206010028980 Neoplasm Diseases 0.000 claims description 2
• 206010053159 Organ failure Diseases 0.000 claims description 2
• 208000018737 Parkinson disease Diseases 0.000 claims description 2
• 241000721454 Pemphigus Species 0.000 claims description 2
• 208000024777 Prion disease Diseases 0.000 claims description 2
• 208000032536 Pseudomonas Infections Diseases 0.000 claims description 2
• 208000017442 Retinal disease Diseases 0.000 claims description 2
• 206010049771 Shock haemorrhagic Diseases 0.000 claims description 2
• 206010040914 Skin reaction Diseases 0.000 claims description 2
• 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
• 206010052779 Transplant rejections Diseases 0.000 claims description 2
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
• 206010046851 Uveitis Diseases 0.000 claims description 2
• 241000700605 Viruses Species 0.000 claims description 2
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 2
• 208000003152 Yellow Fever Diseases 0.000 claims description 2
• 206010000496 acne Diseases 0.000 claims description 2
• 208000005298 acute pain Diseases 0.000 claims description 2
• 239000002671 adjuvant Substances 0.000 claims description 2
• 230000032683 aging Effects 0.000 claims description 2
• 231100000360 alopecia Toxicity 0.000 claims description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
• 201000008937 atopic dermatitis Diseases 0.000 claims description 2
• 201000011510 cancer Diseases 0.000 claims description 2
• 208000025729 dengue disease Diseases 0.000 claims description 2
• 230000001066 destructive effect Effects 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 208000035475 disorder Diseases 0.000 claims description 2
• 208000000718 duodenal ulcer Diseases 0.000 claims description 2
• 206010014599 encephalitis Diseases 0.000 claims description 2
• 206010015037 epilepsy Diseases 0.000 claims description 2
• 201000005917 gastric ulcer Diseases 0.000 claims description 2
• 229940037467 helicobacter pylori Drugs 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
• 206010023332 keratitis Diseases 0.000 claims description 2
• 208000017169 kidney disease Diseases 0.000 claims description 2
• 208000032839 leukemia Diseases 0.000 claims description 2
• 208000019423 liver disease Diseases 0.000 claims description 2
• 201000006417 multiple sclerosis Diseases 0.000 claims description 2
• 208000025487 periodic fever syndrome Diseases 0.000 claims description 2
• 206010034674 peritonitis Diseases 0.000 claims description 2
• 230000002062 proliferating effect Effects 0.000 claims description 2
• 201000000306 sarcoidosis Diseases 0.000 claims description 2
• 231100000241 scar Toxicity 0.000 claims description 2
• 230000035483 skin reaction Effects 0.000 claims description 2
• 231100000430 skin reaction Toxicity 0.000 claims description 2
• 208000020431 spinal cord injury Diseases 0.000 claims description 2
• 238000002054 transplantation Methods 0.000 claims description 2
• 201000008827 tuberculosis Diseases 0.000 claims description 2
• 125000005843 halogen group Chemical group 0.000 claims 6
• 238000002560 therapeutic procedure Methods 0.000 claims 3
• 206010055128 Autoimmune neutropenia Diseases 0.000 claims 2
• 238000009169 immunotherapy Methods 0.000 claims 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
• 206010003694 Atrophy Diseases 0.000 claims 1
• 208000009766 Blau syndrome Diseases 0.000 claims 1
• 206010006458 Bronchitis chronic Diseases 0.000 claims 1
• 201000009273 Endometriosis Diseases 0.000 claims 1
• 208000010412 Glaucoma Diseases 0.000 claims 1
• 102100037850 Interferon gamma Human genes 0.000 claims 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
• 206010038923 Retinopathy Diseases 0.000 claims 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
• 230000037444 atrophy Effects 0.000 claims 1
• 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims 1
• 239000010836 blood and blood product Substances 0.000 claims 1
• 229940125691 blood product Drugs 0.000 claims 1
• 206010006451 bronchitis Diseases 0.000 claims 1
• 208000007451 chronic bronchitis Diseases 0.000 claims 1
• 239000000835 fiber Substances 0.000 claims 1
• 230000002496 gastric effect Effects 0.000 claims 1
• 238000007654 immersion Methods 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 210000003734 kidney Anatomy 0.000 claims 1
• 210000003205 muscle Anatomy 0.000 claims 1
• 201000000050 myeloid neoplasm Diseases 0.000 claims 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
• 239000007787 solid Substances 0.000 description 53
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
• VTDPESCVLKSPCD-JTQLQIEISA-N tert-butyl (2s)-2-(3-amino-2-oxopyridin-1-yl)butanoate Chemical compound CC(C)(C)OC(=O)[C@H](CC)N1C=CC=C(N)C1=O VTDPESCVLKSPCD-JTQLQIEISA-N 0.000 description 21
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 20
• 239000000243 solution Substances 0.000 description 20
• MAJFINHRLBJIQL-UHFFFAOYSA-N benzyl n-(2-oxo-1h-pyridin-3-yl)carbamate Chemical compound OC1=NC=CC=C1NC(=O)OCC1=CC=CC=C1 MAJFINHRLBJIQL-UHFFFAOYSA-N 0.000 description 17
• 235000019439 ethyl acetate Nutrition 0.000 description 16
• 239000003112 inhibitor Substances 0.000 description 15
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• GAOCYGMWQJTKPG-UHFFFAOYSA-N tert-butyl 3-amino-5-fluoro-4-hydroxypentanoate Chemical compound CC(C)(C)OC(=O)CC(N)C(O)CF GAOCYGMWQJTKPG-UHFFFAOYSA-N 0.000 description 12
• 239000002253 acid Substances 0.000 description 10
• 125000004432 carbon atom Chemical group C* 0.000 description 10
• 239000002609 medium Substances 0.000 description 10
• 229920000728 polyester Polymers 0.000 description 10
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 9
• 102100035904 Caspase-1 Human genes 0.000 description 9
• 108090000426 Caspase-1 Proteins 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 239000002552 dosage form Substances 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 8
• 229910000104 sodium hydride Inorganic materials 0.000 description 8
• 102000004091 Caspase-8 Human genes 0.000 description 7
• 108090000538 Caspase-8 Proteins 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 238000003818 flash chromatography Methods 0.000 description 7
• 239000012044 organic layer Substances 0.000 description 7
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 239000011541 reaction mixture Substances 0.000 description 7
• 150000003839 salts Chemical class 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 0 *CC(C(*)=O)NC(C(*)N(C=C(*)C=C1N*)C1=O)=O Chemical compound *CC(C(*)=O)NC(C(*)N(C=C(*)C=C1N*)C1=O)=O 0.000 description 6
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 150000001413 amino acids Chemical group 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 150000002148 esters Chemical class 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 125000006239 protecting group Chemical group 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
• 206010021143 Hypoxia Diseases 0.000 description 5
• 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 238000003782 apoptosis assay Methods 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 230000000699 topical effect Effects 0.000 description 5
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000000217 alkyl group Chemical group 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000007954 hypoxia Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
• 239000011698 potassium fluoride Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• FMEFCRPEUGLMLN-KRWDZBQOSA-N tert-butyl (2s)-2-[2-oxo-3-(phenylmethoxycarbonylamino)pyridin-1-yl]butanoate Chemical compound O=C1N([C@H](C(=O)OC(C)(C)C)CC)C=CC=C1NC(=O)OCC1=CC=CC=C1 FMEFCRPEUGLMLN-KRWDZBQOSA-N 0.000 description 4
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
• GUYNFOUSOJDSPF-VIFPVBQESA-N (2s)-2-(3-acetamido-2-oxopyridin-1-yl)butanoic acid Chemical compound CC[C@@H](C(O)=O)N1C=CC=C(NC(C)=O)C1=O GUYNFOUSOJDSPF-VIFPVBQESA-N 0.000 description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
• XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• 108090000397 Caspase 3 Proteins 0.000 description 3
• 229940123169 Caspase inhibitor Drugs 0.000 description 3
• 102100029855 Caspase-3 Human genes 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 150000001414 amino alcohols Chemical class 0.000 description 3
• 150000001450 anions Chemical class 0.000 description 3
• 230000005775 apoptotic pathway Effects 0.000 description 3
• 229940077388 benzenesulfonate Drugs 0.000 description 3
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 239000012948 isocyanate Chemical class 0.000 description 3
• 150000002513 isocyanates Chemical class 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• SHJOOHKOKCNLCY-LBPRGKRZSA-N tert-butyl (2s)-2-(3-acetamido-2-oxopyridin-1-yl)butanoate Chemical compound CC(C)(C)OC(=O)[C@H](CC)N1C=CC=C(NC(C)=O)C1=O SHJOOHKOKCNLCY-LBPRGKRZSA-N 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 3
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
• NFDZDBDMIZFDES-GJZGRUSLSA-N (3s)-3-[[(2s)-2-(3-acetamido-2-oxopyridin-1-yl)butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(C)=O)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F NFDZDBDMIZFDES-GJZGRUSLSA-N 0.000 description 2
• YNIFSTZXBSNENZ-ZFWWWQNUSA-N (3s)-3-[[(2s)-2-[3-(ethylsulfonylamino)-2-oxo-5-(trifluoromethyl)pyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NS(=O)(=O)CC)=CC(=C1)C(F)(F)F)=O)COC1=C(F)C(F)=CC(F)=C1F YNIFSTZXBSNENZ-ZFWWWQNUSA-N 0.000 description 2
• PBYIIRLNRCVTMQ-UHFFFAOYSA-N 2,3,5,6-tetrafluorophenol Chemical compound OC1=C(F)C(F)=CC(F)=C1F PBYIIRLNRCVTMQ-UHFFFAOYSA-N 0.000 description 2
• VTSFNCCQCOEPKF-UHFFFAOYSA-N 3-amino-1h-pyridin-2-one Chemical class NC1=CC=CN=C1O VTSFNCCQCOEPKF-UHFFFAOYSA-N 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 238000008157 ELISA kit Methods 0.000 description 2
• 102100026693 FAS-associated death domain protein Human genes 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• 229930182816 L-glutamine Natural products 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 238000006751 Mitsunobu reaction Methods 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 125000003342 alkenyl group Chemical group 0.000 description 2
• 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 2
• 150000008052 alkyl sulfonates Chemical class 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• RPDWLBBPGHPVJU-UHFFFAOYSA-N benzyl n-[2-oxo-5-(trifluoromethyl)-1h-pyridin-3-yl]carbamate Chemical compound FC(F)(F)C1=CNC(=O)C(NC(=O)OCC=2C=CC=CC=2)=C1 RPDWLBBPGHPVJU-UHFFFAOYSA-N 0.000 description 2
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229910052799 carbon Chemical group 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 210000003710 cerebral cortex Anatomy 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 210000003618 cortical neuron Anatomy 0.000 description 2
• 125000000392 cycloalkenyl group Chemical group 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007919 intrasynovial administration Methods 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 150000002576 ketones Chemical group 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 239000003208 petroleum Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 229920001451 polypropylene glycol Polymers 0.000 description 2
• 235000003270 potassium fluoride Nutrition 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000010992 reflux Methods 0.000 description 2
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical group CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 150000003871 sulfonates Chemical class 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
• ZWHOTPNCEFWATE-CQSZACIVSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-CQSZACIVSA-N 0.000 description 1
• YZHHZRAWZLMMIC-DLDKDUQYSA-N (3S,4S)-3-[2-(3-acetamido-2-oxopyridin-1-yl)butanoylamino]-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound C(C)(=O)NC=1C(N(C=CC1)C(C(=O)N[C@@H](CC(=O)O)[C@@H](COC1=C(C(=CC(=C1F)F)F)F)O)CC)=O YZHHZRAWZLMMIC-DLDKDUQYSA-N 0.000 description 1
• MYPRERWTTVXKPD-VYRBHSGPSA-N (3s)-3-[2-(3-benzamido-2-oxopyridin-1-yl)butanoylamino]-5-fluoro-4-oxopentanoic acid Chemical compound O=C1N(C(C(=O)N[C@@H](CC(O)=O)C(=O)CF)CC)C=CC=C1NC(=O)C1=CC=CC=C1 MYPRERWTTVXKPD-VYRBHSGPSA-N 0.000 description 1
• UQIMPDYZAGYJAQ-CVRLYYSRSA-N (3s)-3-[2-(3-benzamido-2-oxopyridin-1-yl)propanoylamino]-5-fluoro-4-oxopentanoic acid Chemical compound O=C1N(C(C(=O)N[C@@H](CC(O)=O)C(=O)CF)C)C=CC=C1NC(=O)C1=CC=CC=C1 UQIMPDYZAGYJAQ-CVRLYYSRSA-N 0.000 description 1
• XDOGUBPNFQEBME-MLCCFXAWSA-N (3s)-3-[2-[3-[(2,6-dichlorobenzoyl)amino]-2-oxopyridin-1-yl]butanoylamino]-5-fluoro-4-oxopentanoic acid Chemical compound O=C1N(C(C(=O)N[C@@H](CC(O)=O)C(=O)CF)CC)C=CC=C1NC(=O)C1=C(Cl)C=CC=C1Cl XDOGUBPNFQEBME-MLCCFXAWSA-N 0.000 description 1
• WCOVPAZDXWOPHL-OALUTQOASA-N (3s)-3-[[(2s)-2-(3-benzamido-2-oxopyridin-1-yl)butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)C=2C=CC=CC=2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F WCOVPAZDXWOPHL-OALUTQOASA-N 0.000 description 1
• ISZMEKMHQPHJBI-HOTGVXAUSA-N (3s)-3-[[(2s)-2-[3-(2-methylpropanoylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)C(C)C)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F ISZMEKMHQPHJBI-HOTGVXAUSA-N 0.000 description 1
• QRDXVOPKYPVYFR-OALUTQOASA-N (3s)-3-[[(2s)-2-[3-(benzenesulfonamido)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NS(=O)(=O)C=2C=CC=CC=2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F QRDXVOPKYPVYFR-OALUTQOASA-N 0.000 description 1
• COOHVRSCFUELIN-HOTGVXAUSA-N (3s)-3-[[(2s)-2-[3-(butanoylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C1C(NC(=O)CCC)=CC=CN1[C@@H](CC)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F COOHVRSCFUELIN-HOTGVXAUSA-N 0.000 description 1
• POHDIDBHHYMTOV-HOTGVXAUSA-N (3s)-3-[[(2s)-2-[3-(cyclopropanecarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)C2CC2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F POHDIDBHHYMTOV-HOTGVXAUSA-N 0.000 description 1
• PJUZUWZWUSYYAV-IRXDYDNUSA-N (3s)-3-[[(2s)-2-[3-(diethylcarbamoylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)N(CC)CC)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F PJUZUWZWUSYYAV-IRXDYDNUSA-N 0.000 description 1
• TYVIXBHDXVZZBB-GJZGRUSLSA-N (3s)-3-[[(2s)-2-[3-(ethylcarbamoylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C1C(NC(=O)NCC)=CC=CN1[C@@H](CC)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F TYVIXBHDXVZZBB-GJZGRUSLSA-N 0.000 description 1
• JAHIMDJYXHSFOB-YWZLYKJASA-N (3s)-3-[[(2s)-2-[3-(ethylsulfonylamino)-2-oxopyridin-1-yl]-3-methylbutanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C1C(NS(=O)(=O)CC)=CC=CN1[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F JAHIMDJYXHSFOB-YWZLYKJASA-N 0.000 description 1
• TZDWCSIKJQEWBK-GJZGRUSLSA-N (3s)-3-[[(2s)-2-[3-(ethylsulfonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NS(=O)(=O)CC)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F TZDWCSIKJQEWBK-GJZGRUSLSA-N 0.000 description 1
• CDOSQARWOSCEIO-HOTGVXAUSA-N (3s)-3-[[(2s)-2-[3-(furan-2-carbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)C=2OC=CC=2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F CDOSQARWOSCEIO-HOTGVXAUSA-N 0.000 description 1
• UKLWQLNSKRIUHT-IRXDYDNUSA-N (3s)-3-[[(2s)-2-[3-(furan-3-carbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)C2=COC=C2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F UKLWQLNSKRIUHT-IRXDYDNUSA-N 0.000 description 1
• WQNDPVUOABHOHK-KBPBESRZSA-N (3s)-3-[[(2s)-2-[3-(methoxycarbonylamino)-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)OC)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F WQNDPVUOABHOHK-KBPBESRZSA-N 0.000 description 1
• OLBNRFXZJWGPAZ-GJZGRUSLSA-N (3s)-3-[[(2s)-2-[3-[(2-methoxyacetyl)amino]-2-oxopyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)COC)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F OLBNRFXZJWGPAZ-GJZGRUSLSA-N 0.000 description 1
• IRLFUPPMVBIQPJ-ZFWWWQNUSA-N (3s)-3-[[(2s)-2-[3-acetamido-2-oxo-5-(trifluoromethyl)pyridin-1-yl]butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(C)=O)=CC(=C1)C(F)(F)F)=O)COC1=C(F)C(F)=CC(F)=C1F IRLFUPPMVBIQPJ-ZFWWWQNUSA-N 0.000 description 1
• BSQFSDNSBVFCMP-HOTGVXAUSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(1,2-thiazole-3-carbonylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)C2=NSC=C2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F BSQFSDNSBVFCMP-HOTGVXAUSA-N 0.000 description 1
• JLNCKSRIPFIIQO-GJZGRUSLSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(1,3-thiazol-2-ylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC=2SC=CN=2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F JLNCKSRIPFIIQO-GJZGRUSLSA-N 0.000 description 1
• YMUNHUXADLBEAW-HOTGVXAUSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(propan-2-ylsulfonylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NS(=O)(=O)C(C)C)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F YMUNHUXADLBEAW-HOTGVXAUSA-N 0.000 description 1
• MLQUMDDGQXJMRT-GJZGRUSLSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(propanoylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)CC)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F MLQUMDDGQXJMRT-GJZGRUSLSA-N 0.000 description 1
• HPMHWQXVXCFGOT-HOTGVXAUSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(propylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C1C(NCCC)=CC=CN1[C@@H](CC)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F HPMHWQXVXCFGOT-HOTGVXAUSA-N 0.000 description 1
• ARTMIRNOSHQCJJ-HOTGVXAUSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(propylsulfonylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C1C(NS(=O)(=O)CCC)=CC=CN1[C@@H](CC)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1F ARTMIRNOSHQCJJ-HOTGVXAUSA-N 0.000 description 1
• JYAOMNUSTFDKDW-ROUUACIJSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(pyridine-3-carbonylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)C=2C=NC=CC=2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F JYAOMNUSTFDKDW-ROUUACIJSA-N 0.000 description 1
• YTKJLMYIPVCHIX-IRXDYDNUSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-(pyrrolidine-1-carbonylamino)pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)N2CCCC2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F YTKJLMYIPVCHIX-IRXDYDNUSA-N 0.000 description 1
• NOVBUHVDXWNKEO-PMACEKPBSA-N (3s)-4-oxo-3-[[(2s)-2-[2-oxo-3-[(2-phenylacetyl)amino]pyridin-1-yl]butanoyl]amino]-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid Chemical compound O=C([C@H](CC(O)=O)NC(=O)[C@H](CC)N1C(C(NC(=O)CC=2C=CC=CC=2)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F NOVBUHVDXWNKEO-PMACEKPBSA-N 0.000 description 1
• LEYWABSCAQSKFE-ZENAZSQFSA-N (3s)-5-fluoro-3-[2-[3-[[2-(3-methylphenyl)acetyl]amino]-2-oxopyridin-1-yl]butanoylamino]-4-oxopentanoic acid Chemical compound O=C1N(C(C(=O)N[C@@H](CC(O)=O)C(=O)CF)CC)C=CC=C1NC(=O)CC1=CC=CC(C)=C1 LEYWABSCAQSKFE-ZENAZSQFSA-N 0.000 description 1
• HXXYFTAEZIIAOT-ATNAJCNCSA-N (3s)-5-fluoro-3-[2-[5-methyl-2-oxo-3-[(2-phenylacetyl)amino]pyridin-1-yl]butanoylamino]-4-oxopentanoic acid Chemical compound O=C1N(C(C(=O)N[C@@H](CC(O)=O)C(=O)CF)CC)C=C(C)C=C1NC(=O)CC1=CC=CC=C1 HXXYFTAEZIIAOT-ATNAJCNCSA-N 0.000 description 1
• QHOYFFWYJHGYQI-LSLKUGRBSA-N (3s)-5-fluoro-3-[[4-methyl-2-[2-oxo-3-(propanoylamino)pyridin-1-yl]pentanoyl]amino]-4-oxopentanoic acid Chemical compound CCC(=O)NC1=CC=CN(C(CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)CF)C1=O QHOYFFWYJHGYQI-LSLKUGRBSA-N 0.000 description 1
• DRXYFHFLXMCLDF-PXYINDEMSA-N (3s)-5-fluoro-4-oxo-3-[2-[2-oxo-3-(propanoylamino)pyridin-1-yl]butanoylamino]pentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CF)NC(=O)C(CC)N1C=CC=C(NC(=O)CC)C1=O DRXYFHFLXMCLDF-PXYINDEMSA-N 0.000 description 1
• DWYNLERSIIBXJF-UEWDXFNNSA-N (3s)-5-fluoro-4-oxo-3-[2-[2-oxo-3-(propanoylamino)pyridin-1-yl]pentanoylamino]pentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CF)NC(=O)C(CCC)N1C=CC=C(NC(=O)CC)C1=O DWYNLERSIIBXJF-UEWDXFNNSA-N 0.000 description 1
• VVVLTCNPSCSSPT-UMJHXOGRSA-N (3s)-5-fluoro-4-oxo-3-[2-[2-oxo-3-(propanoylamino)pyridin-1-yl]propanoylamino]pentanoic acid Chemical compound CCC(=O)NC1=CC=CN(C(C)C(=O)N[C@@H](CC(O)=O)C(=O)CF)C1=O VVVLTCNPSCSSPT-UMJHXOGRSA-N 0.000 description 1
• OFCUAHSDAKGDGY-BHWOMJMDSA-N (3s)-5-fluoro-4-oxo-3-[2-[2-oxo-3-[(2-phenylacetyl)amino]pyridin-1-yl]butanoylamino]pentanoic acid Chemical compound O=C1N(C(C(=O)N[C@@H](CC(O)=O)C(=O)CF)CC)C=CC=C1NC(=O)CC1=CC=CC=C1 OFCUAHSDAKGDGY-BHWOMJMDSA-N 0.000 description 1
• FDJXFXLXQRQLPI-VYIIXAMBSA-N (3s)-5-fluoro-4-oxo-3-[2-[2-oxo-3-[(2-phenylacetyl)amino]pyridin-1-yl]propanoylamino]pentanoic acid Chemical compound O=C1N(C(C(=O)N[C@@H](CC(O)=O)C(=O)CF)C)C=CC=C1NC(=O)CC1=CC=CC=C1 FDJXFXLXQRQLPI-VYIIXAMBSA-N 0.000 description 1
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• TUMNHQRORINJKE-UHFFFAOYSA-N 1,1-diethylurea Chemical compound CCN(CC)C(N)=O TUMNHQRORINJKE-UHFFFAOYSA-N 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• FGGLAFQQOCBWMY-UHFFFAOYSA-N 1,2-thiazole-3-carbonyl chloride Chemical compound ClC(=O)C=1C=CSN=1 FGGLAFQQOCBWMY-UHFFFAOYSA-N 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
• HKIPCXRNASWFRU-UHFFFAOYSA-N 1,3-difluoropropan-2-one Chemical compound FCC(=O)CF HKIPCXRNASWFRU-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• ZTEHOZMYMCEYRM-UHFFFAOYSA-N 1-chlorodecane Chemical compound CCCCCCCCCCCl ZTEHOZMYMCEYRM-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
• OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
• DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
• MPYSGONFNUUCBN-UHFFFAOYSA-N 3-(1,3-thiazol-2-ylamino)-1h-pyridin-2-one Chemical compound O=C1NC=CC=C1NC1=NC=CS1 MPYSGONFNUUCBN-UHFFFAOYSA-N 0.000 description 1
• RMPQWJZTCGUTRY-UHFFFAOYSA-N 3-amino-5-fluoro-4-hydroxypentanoic acid Chemical compound OC(=O)CC(N)C(O)CF RMPQWJZTCGUTRY-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
• XWLBYEBHQNSCKA-UHFFFAOYSA-N 5-amino-1h-pyrimidin-6-one Chemical compound NC1=CN=CN=C1O XWLBYEBHQNSCKA-UHFFFAOYSA-N 0.000 description 1
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000022715 Autoinflammatory syndrome Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• DJKSNLKSZFMQPD-UHFFFAOYSA-N C1=CC=C2C(=O)O[IH]C2=C1 Chemical compound C1=CC=C2C(=O)O[IH]C2=C1 DJKSNLKSZFMQPD-UHFFFAOYSA-N 0.000 description 1
• WKRJMFJKARFMHN-LEQYJYOASA-N CC[C@@H](C(NC(C1)(C1C(O)=O)C(COc(c(F)c(cc1F)F)c1F)=O)=O)N(C=CC=C1NC(C)=O)C1=O Chemical compound CC[C@@H](C(NC(C1)(C1C(O)=O)C(COc(c(F)c(cc1F)F)c1F)=O)=O)N(C=CC=C1NC(C)=O)C1=O WKRJMFJKARFMHN-LEQYJYOASA-N 0.000 description 1
• ZDSDYSRLSRPBRM-LOACHALJSA-N CC[C@@H](C(NC(CC(O)=O)C(CF)=O)=O)N(C=CC=C1NC(c2ccccn2)=O)C1=O Chemical compound CC[C@@H](C(NC(CC(O)=O)C(CF)=O)=O)N(C=CC=C1NC(c2ccccn2)=O)C1=O ZDSDYSRLSRPBRM-LOACHALJSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 102000004068 Caspase-10 Human genes 0.000 description 1
• 108090000572 Caspase-10 Proteins 0.000 description 1
• 102000004046 Caspase-2 Human genes 0.000 description 1
• 108090000552 Caspase-2 Proteins 0.000 description 1
• 102000004039 Caspase-9 Human genes 0.000 description 1
• 108090000566 Caspase-9 Proteins 0.000 description 1
• 241000819038 Chichester Species 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• HFMMGOZDEMJQQV-IAXJKZSUSA-N ClC1=C(C(=O)NC=2C(N(C=CC2)C(C(=O)N[C@@H](CC)C(CF)=O)C)=O)C(=CC=C1)Cl Chemical compound ClC1=C(C(=O)NC=2C(N(C=CC2)C(C(=O)N[C@@H](CC)C(CF)=O)C)=O)C(=CC=C1)Cl HFMMGOZDEMJQQV-IAXJKZSUSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 230000008265 DNA repair mechanism Effects 0.000 description 1
• 108010049207 Death Domain Receptors Proteins 0.000 description 1
• 102000009058 Death Domain Receptors Human genes 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010012667 Diabetic glaucoma Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 102000007989 Effector Caspases Human genes 0.000 description 1
• 108010089510 Effector Caspases Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• ZSDDYDQPQVCZDG-KNVGNIICSA-N FCC([C@H](CC)NC(C(CC)N1C(C(=CC=C1)NC(=O)C1=NC=CC=C1)=O)=O)=O Chemical compound FCC([C@H](CC)NC(C(CC)N1C(C(=CC=C1)NC(=O)C1=NC=CC=C1)=O)=O)=O ZSDDYDQPQVCZDG-KNVGNIICSA-N 0.000 description 1
• 102000015212 Fas Ligand Protein Human genes 0.000 description 1
• 108010039471 Fas Ligand Protein Proteins 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 1
• 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 102000003777 Interleukin-1 beta Human genes 0.000 description 1
• 108090000193 Interleukin-1 beta Proteins 0.000 description 1
• 102000003810 Interleukin-18 Human genes 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108010064983 Ovomucin Proteins 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 229920002230 Pectic acid Polymers 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical group [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 150000001299 aldehydes Chemical group 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• FWKLAPCDJJGCFU-UHFFFAOYSA-N benzyl n-(5-methyl-2-oxo-1h-pyridin-3-yl)carbamate Chemical compound CC1=CNC(=O)C(NC(=O)OCC=2C=CC=CC=2)=C1 FWKLAPCDJJGCFU-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000004517 catalytic hydrocracking Methods 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 230000003727 cerebral blood flow Effects 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical class ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
• 208000019069 chronic childhood arthritis Diseases 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000005595 deprotonation Effects 0.000 description 1
• 238000010537 deprotonation reaction Methods 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 1
• HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• BTUIFMCWPFMNRG-UHFFFAOYSA-N furan-3-carbonyl chloride Chemical compound ClC(=O)C=1C=COC=1 BTUIFMCWPFMNRG-UHFFFAOYSA-N 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960002743 glutamine Drugs 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 238000007327 hydrogenolysis reaction Methods 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000023589 ischemic disease Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
• PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000007971 neurological deficit Effects 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002825 nitriles Chemical group 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000012074 organic phase Substances 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 238000005897 peptide coupling reaction Methods 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
• DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
• WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 235000018102 proteins Nutrition 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
• ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 238000012154 short term therapy Methods 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
• UPRLOYNUXQZAPJ-ZCFIWIBFSA-N tert-butyl (2r)-2-hydroxybutanoate Chemical compound CC[C@@H](O)C(=O)OC(C)(C)C UPRLOYNUXQZAPJ-ZCFIWIBFSA-N 0.000 description 1
• GYFJGLDZURBABD-IBGZPJMESA-N tert-butyl (2s)-2-[2-oxo-3-[phenylmethoxycarbonyl(propyl)amino]pyridin-1-yl]butanoate Chemical compound C=1C=CN([C@@H](CC)C(=O)OC(C)(C)C)C(=O)C=1N(CCC)C(=O)OCC1=CC=CC=C1 GYFJGLDZURBABD-IBGZPJMESA-N 0.000 description 1
• YQBMVAHWJDBUMJ-ROUUACIJSA-N tert-butyl (3s)-3-[[(2s)-2-(3-acetamido-2-oxopyridin-1-yl)butanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound O=C([C@H](CC(=O)OC(C)(C)C)NC(=O)[C@H](CC)N1C(C(NC(C)=O)=CC=C1)=O)COC1=C(F)C(F)=CC(F)=C1F YQBMVAHWJDBUMJ-ROUUACIJSA-N 0.000 description 1
• XLBJWVVZWVHKHY-LJJQOFDWSA-N tert-butyl (3s,4s)-3-[2-(3-acetamido-2-oxopyridin-1-yl)butanoylamino]-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound C([C@@H](O)[C@H](CC(=O)OC(C)(C)C)NC(=O)C(CC)N1C(C(NC(C)=O)=CC=C1)=O)OC1=C(F)C(F)=CC(F)=C1F XLBJWVVZWVHKHY-LJJQOFDWSA-N 0.000 description 1
• ZVVDKMXBSCVRCX-UHFFFAOYSA-N tert-butyl 2-phenoxypentanoate Chemical compound C(C)(C)(C)OC(C(CCC)OC1=CC=CC=C1)=O ZVVDKMXBSCVRCX-UHFFFAOYSA-N 0.000 description 1
• HHEDTMQFVNVGQF-UHFFFAOYSA-N tert-butyl 3-amino-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate Chemical compound CC(C)(C)OC(=O)CC(N)C(O)COC1=C(F)C(F)=CC(F)=C1F HHEDTMQFVNVGQF-UHFFFAOYSA-N 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 150000003585 thioureas Chemical class 0.000 description 1
• 229960000103 thrombolytic agent Drugs 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 150000008648 triflates Chemical class 0.000 description 1
• 229910052722 tritium Chemical group 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1